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BACKGROUND Schistosomiasis mansoni is a poverty-related parasitic infection that has a variety of clinical manifestations. 
We consider the disability and deaths caused by schistosomiasis unacceptable for a tool-ready disease. Its condition in Brazil 
warrants an analysis that will enable better understanding of the local health losses and contribute to the complex decision-
making process.
OBJECTIVE This study estimates the cost of schistosomiasis in Brazil in 2015.
METHODS We conducted a cost of illness study of schistosomiasis mansoni in Brazil in 2015 based on a prevalence approach 
and from a societal perspective. The study included 26,499 schistosomiasis carriers, 397 hepatosplenic cases, 48 cases with 
the neurological form, 284 hospitalisations, and 11,368.26 years of life lost (YLL) of which 5,187 years are attributable to 
economically active age groups.
RESULTS The total cost of schistosomiasis mansoni in Brazil was estimated to be US$ 41,7million in 2015 with 94.61% of this 
being indirect costs.
CONCLUSIONS The economic burden of schistosomiasis mansoni in Brazil is high and results in the loss of productivity. Its 
persistence in Brazil is a challenge to public health and requires inter-sectorial interventions in areas such as indoor water supply, 
basic sanitation, and education.
Key words: schistosomiasis mansoni - cost of illness
Schistosomiasis mansoni is a poverty-related para-
sitic infection characterised by various clinical manifes-
tations: milder symptoms such as malnutrition, anaemia, 
abdominal pain, and diarrhoea; and more severe condi-
tions including temporary paralysis (neurological cases) 
and upper gastrointestinal bleeding (hepatosplenic cas-
es).(1) Portal fibroses may reach up to 20% of infected 
cases in endemic areas.(2) It is transmitted mainly through 
skin contact with fresh water contaminated by Schisto-
soma mansoni larvae. In endemic areas with poor sani-
tation, human faeces containing S. mansoni eggs may 
reach water sources through snail hosts, completing the 
transmission cycle.(3) Transmission, infection, morbidity, 
and mortality are closely related to social, economic, and 
environmental conditions.(4)
Historically, schistosomiasis mansoni has been en-
demic in Brazil. However, its geographical distribution 
in Brazilian states is not homogenous, even in endemic 
cities. The country has 27 states, and schistosomiasis is 
present in 19 of these states where in nine states the dis-
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ease is endemic. This disease has focal transmission in 10 
states.(5) For more than 20 years, schistosomiasis has been 
the target of a National Control Program (PCE) aimed at 
the detection and treatment of infected people. Through-
out these years, the prevalence, morbidity, and mortality 
related to schistosomiasis have decreased.(6,7) However, 
severe cases and death continue to occur. Schistosomiasis 
is considered a tool-ready disease, and Brazil is a country 
that theoretically has all the necessary conditions to elimi-
nate chronic and severe cases of schistosomiasis.
According to official health information systems, 
there were 175 hospitalisations and 461 deaths due to 
schistosomiasis in 2015.(7,8) Considering the natural his-
tory of schistosomiasis, the common chain of events in-
volved in death by schistosomiasis mansoni(1,3) and the 
social condition of the cases, people at the late stages 
of the disease would require hospitalisation, normally in 
public health facilities. Therefore, the number of hospi-
talisations appears to be underestimated.
As far as surveillance is concerned, two information 
systems are available in Brazil. SINAN_ESQ, a passive 
system, is exclusively aimed at severe cases and new 
cases found in areas where schistosomiasis transmis-
sion has not been previously reported. The other system, 
SISPCE, applies to known endemic areas and focuses on 
active case searches accomplished through community 
stool surveys. In 2014, more than 6,500 cases were re-
ported to SINAN_ESQ and 33,357 carriers of schistoso-
miasis mansoni were declared in SISPCE.(9,10)
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Brazil has a complicated epidemiological scenario 
especially in many schistosomiasis endemic states and 
municipalities characterised by the prevalence of chronic 
diseases such as hypertension and diabetes, incidence of 
infectious diseases, seasonal dengue epidemics, and most 
recently, Zika virus infection with the emergence of con-
genital neurological damages. Nevertheless, the persistent 
disabilities and deaths caused by schistosomiasis (which 
consequently increase health expenditures) remain to be 
addressed. This warrants an analysis that would enhance 
the understanding of health-related losses and contribute 
to the complex decision-making process.
In studying the costs associated with a disease, an 
important hypothesis is that these costs would otherwise 
provide potential benefits for the population if such a 
disease is either controlled or eliminated. Thus, quanti-
fying the opportunity costs is greatly relevant for the af-
fected population and poverty-related diseases.(11) There-
fore, this study estimates the cost of schistosomiasis in 
Brazil in 2015.
MATERIALS AND METHODS
Based on the prevalence approach, we conducted a 
study on the cost of the disease caused by S. mansoni(12) in 
Brazil to determine the economic burden of schistosomia-
sis in 2015. We used the Brazilian Unified Health System 
(SUS) and employed a societal perspective with the Bra-
zilian population living with schistosomiasis as the target.
Definition of the study population - In this study, the 
population used to estimate the cost burden of the dis-
ease was based on the records of individuals who tested 
positive for S. mansoni reported to SISPCE, those with 
neurological and hepatosplenic forms of the disease as 
registered in SINAN_ESQ, those who were hospitalised 
due to schistosomiasis as registered in the Hospital In-
formation System (SIH-SUS) and those who died due to 
schistosomiasis as reported in the Mortality Informa-
tion System (SIM). This population is identified as Base 
Case (Table I).
The populations simulated for the sensitivity analy-
sis considered the results from the National Survey on 
Schistosomiasis and Soil-transmitted helminths,(5) using 
estimate and confidence interval limits (95% CI). In the 
survey, the prevalence of infection was estimated to be 
0.99% (IC 95% 0.22% - 1.78%). The distribution of in-
fected people with clinical forms included in this study 
was based on the registration of cases from the state of 
Minas Gerais (SINAN_ESQ_MG) as reported at SIN-
AN_ESQ, considering that Minas Gerais established 
that any clinical form of schistosomiasis is a disease of 
compulsory notification. The SINAN_ESQ_MG pro-
vided reports of the positive cases (whether symptomatic 
or not), which were identified in active searches or local 
surveys, as well as late or ectopic forms identified in a 
passive manner. In the other states of the Federation, re-
ports to SINAN_ESQ are restricted to severe, ectopic, or 
positive cases. We considered reports from the SINAN_
ESQ_MG as representative of the disease distribution in 
terms of clinical form given that SISPCE only registers 
the infection, not distinguishing the clinical form of the 
disease, which is essential information to estimate costs.
We found 6,305 registered cases from the national 
SINAN_ESQ database, of which 5,860 (92.9%) were 
intestinal or hepatointestinal, 397 (6.3%) were hepato-
splenic, and 48 (0.7%) were neurological cases. After an-
TABLE I
Detailed study population according to the clinical form and events considered for disease cost estimations. Brazil, 2015
Category of cases/ events for cost estimation Base case Scenario A Scenario B Scenario C
Performed stool sample tests 654,321 449,791 2,024,061 3,639,222
Schistosoma mansoni infection carriers 26,499 449,791 2,024,061 3,639,222
Hepatosplenic form of the disease (2.5% of infected people) 397 11,245 50,601 90,981
Neurologic form of the disease (0.7% of infected people) 48 3,149 14,168 25,475
Hospitalisations (6.4% of chronic forms) 275 921 4,145 7,453
Hospitalisations in intensive therapy care unit (3.2% of hospitalisations) 9 29 133 239
Cases that paid transportation for treatment (22.5% of severe forms) 100 3,238 14,573 26,202
Users that needed to pay a caregiver (3.5% of severe forms) 16 504 2,226 4,076
Economically active cases for which work leave and disease aid costs 
are applied among neurological forms (22%)
87 2,473 11,132 20,016
Economically active cases for which work leave and disease aid costs 
are applied among neurological forms (22%)
10 693 3,117 5,604
Years of life lost due to premature death (constant) 5,187 5,187 5,187 5,187
Base case: records from national information systems are the source of the numbers regarding the categories of cases/events. 
Measurements were applied only for cases with demand for transportation, caregiver, leave, and disease aid; scenario A: cases 
estimated based on the confidence interval lower limit (95%CILL) of the prevalence estimated in the national survey of schisto-
somiasis; scenario B: cases estimated based on the prevalence estimated in the national survey of schistosomiasis; scenario C: 
cases estimated based on the 95%CI upper limit of the prevalence estimated in the national survey of schistosomiasis.
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alysing the SINAN_ESQ_MG database, the cases were 
stratified according to the clinical forms established in 
the schistosomiasis investigation form. We observed 
3,708 cases (91; 2.5%) hepatosplenic, 26 (0.7%) neuro-
logical, and 3,591 (96.8%) intestinal or hepatointestinal 
cases from the SINAN_ESQ_MG database. Such pro-
portions were applied to the number of estimated infect-
ed individuals using the prevalence and the 95% CI to 
simulate the three scenarios of the sensitivity analyses. 
These populations were identified as Scenario A (lower 
limit of the 95% CI), Scenario B (estimate), and Scenario 
C (upper limit of the 95% CI). Table I provides a descrip-
tion of the number of cases and events considered for 
estimating the cost of schistosomiasis.
The potential years of life lost (YLL) by premature 
death was used to estimate part of the indirect costs. 
YLL was calculated using records of deaths caused by 
schistosomiasis from the SIM. Relevant information 
from the death certificate (DC) signifying the cause of 
death, were used as the main selection criteria. Such da-
tabase showed 529 deaths, and schistosomiasis was not 
indicated as the basic cause in 155 deaths. We conduct-
ed an individual assessment of each record to identify 
deaths that indicated schistosomiasis as the basic cause, 
but among the 155 records that had CID10 of schistoso-
miasis in part 1 of the DC, we could not define it as the 
basic cause. We attempted to develop a clinical causal 
relationship between the CID completed in lines ‘a’ to 
‘d’ from the DC and to identify the basic cause of death 
according to the sequence of DC completion. We con-
sidered the causes of deaths due to schistosomiasis to 
include cases of hematemesis, bleeding of oesophageal 
varices, hypovolemic shock by hematemesis, death due 
to hepatic insufficiency, and portal hypertension with 
portal vein thrombosis, encompassing 406 deaths.
YLL was estimated based on the product between 
the number of deaths and the life expectancy at the age 
of death. Records on 406 deaths were stratified accord-
ing to gender and detailed age range (every five years 
from 0 to 65 years or older: 0, 1-4, 5-9, 10-14, and so on 
up to 65). The median of ages from each age range was 
established as the mean age in which there was occur-
rence of death in the respective age group. The study 
used the life table from the ‘Brazilian Institute of Ge-
ography and Statistics of 2015’ with life expectancies of 
71.9 and 79.1 years for males and females, respectively.
Categories, costs and hypotheses - We made an ex-
tensive cost inventory for the ‘direct healthcare costs’ 
category including the items related to stool sample in-
vestigations or search for cases in the community; the 
methods used for diagnosing the disease’s clinical forms 
and following-up the patients’ evolution; and the infec-
tion treatments and clinical repercussions of chronic and 
neurological forms. Transportation for treatment and 
caregiver’s payment were considered non-healthcare 
direct costs. These costs were identified through inter-
views with 174 schistosomiasis patients that had outpa-
tient follow-up visits (carried out from July to December 
of 2015) at the Hospital das Clínicas from Universidade 
Federal de Pernambuco (AE/HC/UFPE). Indirect costs 
included values attributed to YLL due to premature 
death, work leave, and disease aid of the economically 
active population and were estimated using the human 
capital method. This method estimates present human 
capital value as a representation of a person’s future 
gains based on the hypothesis that the person’s future 
gains represent his future productivity.(12)
To establish the cost items included in this study as 
well as their measurement and valuation parameters (see 
Table II), we used specific schistosomiasis surveillance 
guides from the Brazilian Ministry of Health. We also 
used information from specialists in the basic protocol 
of patients with digestive forms of the disease, and stan-
dard laboratorial operational procedures and data col-
lected in the outpatient clinic of schistosomiasis (AE/
HC/UFPE) as references. The amounts attributed to 
the items were based on operational and epidemiologi-
cal parameters obtained from the analysis of SISPCE, 
SINAN_ESQ, SIH-SUS, and clinical protocols. When a 
certain parameter is unavailable, we estimated the val-
ues using clinical recommendations as reference.
The monetary values attributed to the items were 
searched in systems or tables of prices within a domestic 
scope. If an item’s price varied throughout the year, we 
used a monthly average. When we could not find a single 
national reference, we chose the price reference from en-
demic states. The parameters described in text box one 
were applied to the values with details provided in the 
Supplementary data (Table). The years of life lost due to 
premature death remained constant in all the scenarios. 
We estimated the values for each investigated case in-
cluded in the survey and for each hepatosplenic schisto-
somiasis and neurological case. Based on the individual 
values, we estimated the cost of the disease for the base 
case and performed a sensitivity analysis in three dif-
ferent scenarios. The values obtained in Brazilian Reais 
were converted to US dollars based on the prevailing ex-
change rate on July 1,as quoted from 2015 (3.263).
We used the following data sources: SIM; SIH-SUS; 
medical records and interviews with patients from AE/
HC/UFPE; scientific literature; management system of 
the procedures, drugs and orthesis, prosthesis, and spe-
cial devices from the Brazilian Unified Health System 
(SIGTAP); price database of the Brazilian Department 
of Health; websites from the Planning Department, 
Health Department, Health State and City Offices; Pub-
lic Tender Offers; and clinical protocols.
RESULTS
The study’s Base Case included costs for 26,499 
schistosomiasis carriers (infected people), 20,646 (77.9%) 
positive case records from the SISPCE, and 5,853 (22.1%) 
reported cases in SINAN. Regarding severe forms of the 
disease and measured events in the costs, we considered 
397 hepatosplenic cases (SINAN), 48 cases with the neu-
rological form (SINAN), 275 hospitalisations in wards 
(SISUS), and nine hospitalisations in ICUs (SISUS).
We included 406 deaths, of which 269 (51.0%) were 
males and 127 (31.2%) occurred in ages that are consid-
ered economically active. Pernambuco and Minas Gerais 
were the residence states of 46.5% (189) of the deaths. 
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TABLE II
Assumptions applied to estimate the cost of Schistosoma mansoni. Brazil, 2015
Category of costs Type of cost General hypotheses
Direct health  
care costs 
Stool sample investigations 
in the endemic or focal 
cities
The stool sample survey is the action to establish the treatment strategy 
based on the percentage of positivity in the place where the transmission has 
been established, with the aim of decreasing the prevalence and avoiding 
the evolution to chronic and severe forms of the disease. Considered items: 
community’s action to distribute the specimen containers by a health 
community worker, sample collection, laboratorial sample processing and 
a Kato-katz thick smear by a technician in clinical analysis, result delivery, 
treatment administration during delivery and registration in specific form.
Diagnosis of the chronic 
digestive and neurological 
forms
Imaging exams and laboratorial analyses recommended in guides on disease 
clinical management or specialised service routines. The proportion of cases, 
according to each clinical form, which used imaging exams, was measured 
from the information obtained in the Brazilian Information System for 
Notifiable Diseases.
Hospitalisations The total of hospitalisations for the Base Case was the exact number of 
hospitalisations registered in the hospital information system (SIHSUS) 
from 2015. We applied the same proportion to the chronic cases of cases 
being monitored at the Schistosomiasis outpatient clinic (AE/HC/UFPE) that 
reported hospitalisation in the last 12 months for the scenarios of sensitivity 
analysis. The applied value was obtained through the average amount of a 
hospitalisation due to schistosomiasis reported in the SIHSUS.
Hospitalisations in intensive 
care unit (ICU)
The number of hospitalisations in the ICU for Base Case was exactly the 
number of hospitalisations in ICU registered in SIHSUS/2015. For the 
scenarios of the analysis, we applied the proportion of hospitalised cases 
in ICU among the registrations from SIHSUS/2015. The applied value was 
the average value of a hospitalisation by schistosomiasis in an ICU bed in 
SIHSUS/2015.




Mean value spent with transportation by patients monitored in the outpatient 
clinic (AE/HC/UFPE), applied to the local protocol of two medical 
appointments on average, per year, for each chronic patient. For the Base 
Case and the sensitivity scenarios, we applied the proportion of cases being 
monitored in the outpatient clinic that bore the costs of transportation for the 
follow-up.
Caregiver’s payment Mean value spent with caregiver by patients followed-up in the outpatient 
clinic (AE/HC/PE). For the Base Case and sensitivity scenarios, we applied 
the proportion of cases that paid a caregiver among patients being followed-
up at the outpatient clinic (AE/HC/PE).
Indirect costs Loss of wages due to  
premature death
Annual wage in 2015 (US$: 7,571.76), based on the average wage of US$: 
567.88, including social and labor charges. The annual amount was applied 
to the estimated years of life lost (YLL) due to premature death in the 
economically active age range (15 to 65 years-old). The YLL number was 
kept constant in the Base case and sensitivity scenarios.
Loss of wages due to 
hospitalisation and leave
Number of days lost due to hospitalisation and medical leave was 180 days 
for neurological cases and 90 days for other hospitalised cases. There was a 
77.6% rate of economically active cases, which was the proportion of cases 
being followed at the outpatient clinic with formal employment.
Disease aid Benefit for 22.4% of the chronic cases in the Base Case and in sensitivity 
scenarios. We considered the proportion of cases being followed at the 
outpatient clinic and receiving disease aid due to schistosomiasis. The 
benefit value was calculated using the 2015 rule for workers receiving one 
minimum wage with 5 years of contribution.
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The states with the highest standardised mortality rate 
caused by schistosomiasis were: Alagoas (1.48/100,000 
residents), Pernambuco (1.20/100,000 residents), and 
Sergipe (0.61/100,000 residents) (Table III).
Out of the 406 deaths (Table IV), 172 were in eco-
nomical active ages (15 to 65 years). We calculated 5,187 
YLL in these age groups with men contributing 2,903 
(55.96%) of the YLL.
Among direct healthcare costs, we estimated that 
US$ 2,1 million related to the diagnosis of schistosomia-
sis and its main complications and US$ 147,513.24 to the 
treatment of hepatointestinal and neurological infection 
forms. Non-healthcare direct costs such as transporta-
tion and domestic care from the patients’ perspective 
were estimated to be US$ 1,838.38; and indirect costs 
with leave, disease aid, and premature death totalled 
US$ 39,457,036.56. In the Base Case scenario, consider-
ing only schistosomiasis records of current information 
systems, 94.61% of the cost of illness was attributed to 
indirect costs. The total cost of schistosomiasis was esti-
mated to be US$ 41,706,337.35.
The sensitivity analysis of the costs was performed 
using three scenarios, all of which resulted in total costs 
that were higher than those estimated in the Base Case. 
In Scenario B, which considered the estimate of infected 
people according to the Schistosomiasis National Sur-
vey, the estimated total costs were 72.59% higher than 
those of the Base Case. We also observed that the dis-
ease’s direct costs were higher in all the scenarios, with 
increased proportion to the total cost of the disease. In 
Scenario B (prevalence estimated in the survey), the di-
rect healthcare costs were more than 1,000% higher than 
in the Base Case. In Scenario A (95% CI lower limit of 
the prevalence estimated in the survey), with the low-
est estimated prevalence, the disease cost was 11.55% 
higher than the costs estimated in the Base Case. Table 
V shows the cost breakdown, according to category and 
type of sensitivity analysis.
DISCUSSION
This study estimated 0.18 deaths for every 100 thou-
sand residents in Brazil in 2015; and the highest rates 
were in the endemic states of Alagoas, followed by Per-
nambuco and Sergipe. There were 5,187 years of life lost 
due to premature death in economically active ages, and 
the disease costs were estimated at US$ 41,706,337.35 
with 90% of these costs being indirect costs.
TABLE III
Number of deaths, mortality rate (MR) specific for schistoso-
miasis. Brazil, 2015





Alagoas 54 3,340,528 1.62 1.48
Pernambuco 119 9,345,638 1.27 1.20
Sergipe 15 2,242,948 0.67 0.61
Rio Grande do Norte 4 3,442,158 0.12 0.46
Bahia 54 15,203.851 0.35 0.32
Minas Gerais 70 20,869,033 0.33 0.30
Paraíba 9 3,972,175 0.23 0.22
Espírito Santo 8 3,929,925 0.20 0.17
Distrito Federal 4 2,914,830 0.14 0.12
São Paulo 52 44,396,460 0.12 0.10
Maranhão 6 6,904,298 0.09 0.08
Goiás 5 6,610,683 0.08 0.06
Rondônia 1 1,768,162 0.06 0.05
Rio de Janeiro 4 16,550,009 0.02 0.02
Paraná 1 11,163,023 0.01 0.01
Brazil 406 204,450,380 0.12 0.18
MR: mortality rate. *: direct method of standardisation with 
stratification of deaths and population aged younger than 60, 
equal or older than 60 years. Source: SIM/SVS/MS 2010 Bra-
zilian demographic census and estimates elaborated by the 
Department of Health/SVS/CGIAE.
TABLE IV
Years of life lost (YLL) by schistosomiasis according to gender and per 1,000 residents. Brazil, 2015
Age range
Male Female Total
Deaths YLL Deaths YLL Population Deaths YLL YLL/1,000*
1-4 1 89.51 0 0.00 14,737.740 1 89.51 0.01
5-14 1 80.03 0 0.00 32,671.352 1 80.03 0.00
15-29 3 210.21 2 135.16 51,373.431 5 345.37 0.01
30-44 22 1,169.30 12 647.26 47,437.888 34 1,816.56 0.04
45-59 51 2,032.37 35 1,356.45 34,289.353 86 3,388.82 0.10
60-69 56 1,568.85 55 1,538.11 13,641.753 111 3,106.96 0.23
70-79 39 761.75 62 1,199.70 6,990.107 101 1,961.45 0.28
80+ 33 291.74 34 287.82 3,309.025 67 579.56 0.18
Total 206 6,203.76 200 5,164.49 204,450.649 406 11,368.26 0.06
*: per 1,000 residents. Source: SIM/SVS/MS. Estimates elaborated by the Department of Health/SVS/CGIAE.
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Studies point out a decreasing trend of mortality due 
to schistosomiasis in Brazil,(13,14) which suggests an an-
nual reduction of around 2.8% per year. This decrease 
may be deemed multi-factorial (not mainly due to spe-
cific disease control actions) considering that the coun-
try has also undergone changes in healthcare systems 
and in various social and economic aspects throughout 
the years. However, schistosomiasis mortality reported 
in the SIM may be underestimated. There is a possibil-
ity that schistosomiasis deaths are being hidden by other 
causes in endemic states like Alagoas, Pernambuco, Ser-
gipe, Bahia, and Minas Gerais. An investigation of active 
searches conducted in the largest emergency service of 
Pernambuco found that 30% of the digestive haemorrhage 
cases assisted in the unit was due to schistosomiasis.(15)
The chronic character of the disease should be con-
sidered when analysing its impact on mortality. Despite 
its potential severity, early diagnosis of the infection, 
even of the chronic forms, when followed by proper 
treatment, prevents the potentially lethal complications 
of the disease, especially haemorrhagic manifestations.
(16) Mortality caused by a disease that is closely related 
to poverty is not homogeneous and should be noticed as 
a sentinel indicator for monitoring the disease situation 
in Brazil.(17) The states of Alagoas, Pernambuco and Ser-
gipe exhibited the highest mortality rates. Even though 
Alagoas and Pernambuco showed the highest rates, the 
state of Sergipe may present a more serious concern for 
disease control because aside from its high mortality 
rate, it had the highest prevalence of the disease in the 
country based on the national survey.
The years of life lost due to premature death has been 
one of the indicators used in health loss estimates consid-
ering it is part of the disability-adjusted life year (DALY) 
indicator. The 2015 Global Burden of Disease (GBD) 
study estimated 382,543.93 years of life lost in the world 
from schistosomiases (with around 18,012 YLL in Bra-
zil)(18) and included almost 200 more deaths as compared 
to our study. Additionally, estimates of YLL produced 
by GBD show that Brazil had more YLL attributable 
to schistosomiasis as compared to Nigeria, Indonesia, 
China, and many other low-income countries.(17) Accord-
ing to GBD, Brazil presented 228,101.29 YLL caused by 
neglected tropical diseases and malaria in 2015, and the 
highest numbers of YLL were related to Chagas disease 
(114,313.53), leishmaniasis (37,896,42.701), and dengue 
(38,195.82). Schistosomiasis represented 7.89% of the 
YLL in this group, greater than diseases like cysticerco-
sis (2.02%) and malaria (1.68%).(18) An important aspect 
to be considered regarding the years of life lost due to 
schistosomiasis is its preventability. One may infer that 
its chronic character causes slow reduction of the indica-
tors involved in mortality. However, YLL considers that 
life expectancy at the age of death is higher the lower the 
age is. We observed deaths in people under 30 years-old 
in the states of Sergipe, Pernambuco, Minas Gerais and 
Bahia. The same chronic character of the disease may 
imply that deaths by schistosomiasis in young people 
represent a serious negative indicator of public health. 
This early loss of life significantly impacted the estimat-
ed costs of the disease.
This study presented significant costs associated with 
schistosomiasis even though it is a disease that could 
be prevented through better life conditions and health 
education. This disease is diagnosable and treatable in 
its early stages when measurements of effective control 
are systematically applied. Restoring health is expensive 
and depends on several resources that may be limited or 
rare. Collective treatment strategies of schistosomiasis 
in endemic localities are known to be affordable, cost-
effective,(19,20) and to contribute to the decrease in the 
occurrence of the disease. Consistent with this finding, 
we have estimated treatment cost of US$ 3.83 for each 
case diagnosed in stool sample investigations. There are 
only a few studies on the cost of diseases in Brazil. The 
cost associated with schistosomiasis was higher than 
for visceral leishmaniasis in 2014(21) and lower than for 
diabetes in the state of São Paulo; this is a disease with 
an estimated prevalence for the country of around 6.8% 
of the population older than 18.(22) Despite the method-
ological differences in studies on the cost of diseases, 
the most important thing to consider is that resources for 
healthcare are competitively allocated; and in complex 
epidemiological contexts (with significant prevalence 
of non-communicable diseases), diseases like schistoso-
miasis may lose visibility and priority.
Even if we only consider diagnosis and treatment 
(without the other cost categories nor the disabilities or 
losses of quality of life involved in the schistosomiasis 
burden), control actions in endemic places are expected 
to be more cost-effective than the management of more 
severe forms of the disease. Therefore, the performance 
of the healthcare system in controlling schistosomiasis is 
of paramount importance. Control actions based on stool 
sample diagnosis methods and treatment strategies based 
on positivity percentages are affected by the decrease 
of sensitivity of such methods in low-endemic areas.(23) 
In addition, other researchers suggest that mass treat-
ments in endemic places showed more effectiveness to 
control schistosomiasis transmission.(24) If the treatment 
strategy in high prevalence areas were used, the costs 
associated with diagnosis and treatment of the infection 
as estimated in our study would be even lower. In Brazil, 
the treatment strategy is based on the outcomes of regu-
lar stool sample investigations. In the event of positivity 
lower than 15%, the people who tested positive would 
be treated; between 15% and 25%, those people living 
in the same household as the infected people would be 
treated as well; and above 25%, all people living in the 
entire area would be treated.(6) The effectiveness of this 
strategy still needs to be assessed based on the costs as-
sociated with the disease and on the Kato-Katz sensitiv-
ity in low-prevalence areas.
The economic impact of schistosomiasis on both the 
healthcare system and the people affected by the disease 
is high. Elimination of schistosomiasis as a public health 
problem involves more than actively finding these cases 
and treating affected individuals. A study conducted in 
Kenya that monitored the impact of control programs 
based on collective treatment did not show evidence of 
transmission reduction during the program’s implemen-
tation even though it improved the health of individuals.
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(25) This reinforces the urgent need of improving people’s 
life conditions, especially basic environmental sanita-
tion, and people’s empowerment through health educa-
tion. Brazil needs to improve its basic sanitation. In 2015, 
according to the Report of Public Expenses with Basic 
Sanitation, sewage network was available only to 59% of 
the population and such coverage is not homogeneous.(26) 
In the Northeast, where endemic areas for schistosomia-
sis are found, this access is available for 49% of the cities 
in the urban areas and only for 3.84% in the rural areas. 
The urban areas of the Northeast have 6.7 million houses 
without access to the collector network. The distribu-
tion of such access according to income demonstrates 
inequality considering that the problem is mainly of the 
low-income population. In 2001 and 2015, the percent-
ages of houses without access to the sewage collector 
network were 63% among households with the lowest 
income and 66% for those with income up to three times 
the minimum wages.(26)
Even with the current efforts to control schistosomia-
sis, its profile is still highly related to the conditions of 
life, population vulnerability, and permanent poverty.(4) 
In endemic areas, contracting schistosomiasis does not 
generally occur in isolation. Its occurrence is concurrent 
with other intestinal parasites, other infectious diseases(4) 
or even non-communicable diseases. The impact to eco-
nomic and health conditions and quality of life related 
to this complex epidemiological profile still needs to be 
measured to develop integrated and effective interven-
tions that would improve health and address inequality.(4)
There are limitations in our study, some of which are 
associated with the impact of the number of cases used 
in the accuracy of cost estimation and others are related 
to methodological options. The exclusive use of case 
records in information systems has probably underesti-
mated the cost of schistosomiasis. Considering the dif-
ferences between the clinical forms of the disease, which 
have a direct impact on costs, we needed to stratify the 
cases. Only SINAN presents the clinical form. Among 
more than 20 thousand positive cases registered in 
SISPCE, there may be cases with more advanced stages 
of the disease or with non-specific symptoms requiring 
other treatments (not only the specific pharmacological 
treatment), which would make the direct healthcare costs 
higher than our estimates. Additionally, the sensitivity 
analysis also pointed out more significant direct costs 
in the scenarios even when we used the lower limit of 
the confidence interval of the national survey estimates.
By presenting a study on the cost burden of schis-
tosomiasis mansoni, our main intention is to show the 
economic burden that such a disease could impose on 
the entire society. These costs could represent potential 
benefits if schistosomiasis were eliminated. In our study, 
there were huge indirect costs related to the ‘market value’ 
of future contributions by people affected by the disease 
(had they been treated and thus, continued to work). Al-
though there are some criticisms to this method, alterna-
tives like the willingness to pay method (which may result 
in higher values than the human capital method), are dif-
ficult to use in studies on the cost burden of diseases.(12)
In conclusion - The economic burden of schistoso-
miasis mansoni disease in Brazil is high, and its greater 
impact is related to the loss of productivity. This disease 
is exacerbated by poor living and health conditions in 
endemic areas. Healthcare initiatives designed to elimi-
nate its transmission will not be sustainable without ba-
sic sanitation, access to intra-domiciliary potable water, 
proper shelter, education, and access to healthcare. The 
persistence of this disease in Brazil is a challenge not 
only to public health but also to various sectors, espe-
cially to the political class that has the means to influ-
ence the mobilisation of public resources.
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